Aurobindo Pharma has received final approval from the US Food and Drug Administration for Perampanel Tablets across six strengths.

The approved strengths are 2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg.

Perampanel is the generic equivalent of Fycompa tablets, the reference listed drug marketed by Catalyst Pharmaceuticals.

The approval allows Aurobindo Pharma to manufacture and market the product in the United States.

For a generic pharmaceutical company, USFDA approvals can open the door to additional products and potential revenue opportunities.

Aurobindo said the product will be manufactured at Unit IV of APL Healthcare, its wholly owned subsidiary.

The company currently plans to launch the product in the US market during the third quarter of FY27.

This means the commercial opportunity from the approval is expected to develop after the launch rather than immediately following the regulatory clearance.

According to the company, the approved product had an estimated US market size of $67 million for the twelve months ended August 2026.

This market size represents the overall market for the relevant product and should not be interpreted as potential revenue for Aurobindo alone.

Actual sales will depend on factors such as market share, pricing, competition and the timing of the launch.

The number of strengths approved is also significant because Aurobindo can address the different dosage requirements covered by the product.

Perampanel is used in the treatment of certain forms of seizures associated with epilepsy.

It is indicated for partial onset seizures in patients aged four years and older, with or without secondarily generalized seizures.

It is also indicated as adjunctive therapy for primary generalized tonic clonic seizures in patients aged twelve years and older.

The approval therefore gives Aurobindo another product in the central nervous system therapy segment.

The company has been building a broad generic portfolio for the US market through regulatory filings and product launches.

Aurobindo’s US business remains an important part of its overall formulations operations.

The company has also continued to receive US regulatory approvals across different therapeutic areas.

The Perampanel approval adds another product to this pipeline and provides an opportunity to expand the company’s US product portfolio.

However, regulatory approval by itself does not guarantee a particular level of commercial success.

The US generic pharmaceutical market can be highly competitive, especially when several manufacturers are able to supply the same medicine.

Pricing pressure can therefore influence the revenue and profitability generated from a newly launched generic.

Investors should also watch the actual launch timing because the company has currently indicated Q3 FY27 for commercialisation.

The performance of the product after launch will provide a clearer indication of how much of the addressable market Aurobindo can capture.

Another important factor will be the number of competing generic products available in the US market.

The company’s manufacturing location is also relevant because Unit IV of APL Healthcare will be responsible for producing the approved product.

Efficient manufacturing and consistent regulatory compliance will be important for maintaining supply once commercial sales begin.

Aurobindo has stated that it now has 599 USFDA ANDA approvals, comprising 574 final approvals and 25 tentative approvals.

This approval therefore adds to an already sizeable regulatory portfolio in the United States.

For investors, the bigger picture is whether these approvals can translate into a steady stream of product launches and sustainable US revenue growth.

The Perampanel opportunity should therefore be monitored alongside launch timing, market share, pricing, competition and the company’s broader US formulations performance.

Overall, the approval strengthens Aurobindo Pharma’s US product pipeline and creates another potential revenue opportunity, while the actual financial impact will become clearer after commercial launch.